 NEW YORK, June 24, 2021 PRNewswire -- Elevation Oncology, Inc. Nasdaq: ELEV, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of 16.00 per share. All of the shares are being offered by Elevation Oncology. 